Corbion stock advances on 2025 revenue and margin progress
Published on 07/19/2026 at 11:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Corbion (ISIN NL0010583399) stock is anchored by 2025 results that showed EUR 1.29 billion in revenue, EUR 213 million in adjusted EBITDA, and EUR 418 million in net debt at year-end 2025. The figures come from the companys 2025 annual reporting and give investors a clear read on scale, profitability, and leverage going into 2026.
EUR 1.29 billion revenue
Revenue for fiscal 2025 reached EUR 1.29 billion, while adjusted EBITDA totalled EUR 213 million. That combination implies an adjusted EBITDA margin of about 16.5% for the year, a useful benchmark for comparing operating efficiency across food ingredients and biobased applications.
For a market context anchor, Corbion shares trade on Euronext Amsterdam, and the business remains sensitive to margin delivery rather than only topline growth. The year-end net debt figure of EUR 418 million also matters because it frames how much flexibility the balance sheet had entering 2026.
Margin and debt matter
The company reported EUR 213 million in adjusted EBITDA against EUR 1.29 billion in revenue for 2025, and that ratio is more informative than revenue alone. It points to a business that is still highly dependent on pricing, input costs, and product mix across its nutrition and biobased portfolios.
Net debt of EUR 418 million at 31 December 2025 gives another concrete reference point. Compared with the scale of annual EBITDA, the figure suggests leverage was manageable but still relevant for any future capital allocation or dividend discussion.
Corbion 2025 reporting and investor materials
Key company disclosures on revenue, EBITDA, and net debt remain the most relevant base for assessing Corbion stock through 2026.
Biobased applications
Corbion's biobased applications remain central because they connect revenue, margin, and capital intensity in one portfolio. The 2025 numbers show why investors typically watch mix, operating leverage, and debt together rather than in isolation.
The same logic applies to the nutrition side of the business, where demand trends and pricing can shift EBITDA faster than revenue alone. The 2025 disclosure therefore gives a sharper picture than a simple sales headline would.
Year-end 2025 snapshot
Corbion is a specialty ingredients company focused on food preservation, lactic acid, and biobased building blocks. In 2025, those businesses produced EUR 1.29 billion in revenue, EUR 213 million in adjusted EBITDA, and EUR 418 million in net debt, which is the key three-number frame for the stock.
That snapshot is useful because it combines size, profitability, and leverage in one periodized set of figures. For investors tracking Corbion stock, the next question is whether 2026 can improve the margin profile without stretching the balance sheet.
Shares on Euronext Amsterdam
Corbion stock trades on Euronext Amsterdam. The companys 2025 revenue of EUR 1.29 billion, adjusted EBITDA of EUR 213 million, and year-end net debt of EUR 418 million remain the cleanest dated reference points for the current valuation debate.
Corbion stock facts
- Company: Corbion N.V.
- ISIN: NL0010583399
- Ticker: Euronext Amsterdam: CRBN
- Trading venue: Euronext Amsterdam
- Sector / Industry: Materials / Specialty Chemicals
- Index membership: Not stated here
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
